Richard de Boer

2.3k total citations
42 papers, 1.5k citations indexed

About

Richard de Boer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Richard de Boer has authored 42 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in Richard de Boer's work include Advanced Breast Cancer Therapies (13 papers), Cancer Treatment and Pharmacology (11 papers) and Breast Cancer Treatment Studies (10 papers). Richard de Boer is often cited by papers focused on Advanced Breast Cancer Therapies (13 papers), Cancer Treatment and Pharmacology (11 papers) and Breast Cancer Treatment Studies (10 papers). Richard de Boer collaborates with scholars based in Australia, United States and United Kingdom. Richard de Boer's co-authors include Robert E. Coleman, Holger Eidtmann, Antonio Llombart‐Cussac, N. Davidson, Gϋnter von Minckwitz, Nigel Bundred, Katia Tonkin, Allan Lipton, Philippe Solal‐Céligny and Guenther G. Steger and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Richard de Boer

40 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard de Boer Australia 15 1.2k 409 333 321 282 42 1.5k
Claudine Helg Switzerland 30 536 0.4× 134 0.3× 226 0.7× 106 0.3× 40 0.1× 65 2.9k
Giuseppe Milone Italy 31 851 0.7× 56 0.1× 1.2k 3.5× 103 0.3× 107 0.4× 142 3.2k
Randi Isaacs United States 22 582 0.5× 136 0.3× 588 1.8× 182 0.6× 19 0.1× 41 1.6k
Yaël C. Cohen Israel 19 537 0.4× 88 0.2× 389 1.2× 102 0.3× 19 0.1× 141 1.4k
João Bosco Oliveira Brazil 27 277 0.2× 54 0.1× 546 1.6× 153 0.5× 29 0.1× 73 2.2k
WE Fibbe Netherlands 24 498 0.4× 93 0.2× 257 0.8× 169 0.5× 17 0.1× 36 1.9k
J. Sieper Germany 18 124 0.1× 112 0.3× 199 0.6× 35 0.1× 223 0.8× 84 2.3k
Pamela G. Kidd United States 21 301 0.2× 235 0.6× 248 0.7× 139 0.4× 19 0.1× 43 1.5k
J Cahn France 22 392 0.3× 47 0.1× 282 0.8× 53 0.2× 66 0.2× 70 1.6k
Chirayu Auewarakul Thailand 18 151 0.1× 82 0.2× 237 0.7× 110 0.3× 18 0.1× 63 1.0k

Countries citing papers authored by Richard de Boer

Since Specialization
Citations

This map shows the geographic impact of Richard de Boer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard de Boer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard de Boer more than expected).

Fields of papers citing papers by Richard de Boer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard de Boer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard de Boer. The network helps show where Richard de Boer may publish in the future.

Co-authorship network of co-authors of Richard de Boer

This figure shows the co-authorship network connecting the top 25 collaborators of Richard de Boer. A scholar is included among the top collaborators of Richard de Boer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard de Boer. Richard de Boer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lok, Sheau Wen, Richard de Boer, Laeeq Malik, et al.. (2023). Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer. Breast Cancer Research and Treatment. 198(1). 67–74. 7 indexed citations
2.
Reck, Martin, Tony Mok, Aaron S. Mansfield, et al.. (2022). Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide. Journal of Thoracic Oncology. 17(9). 1122–1129. 17 indexed citations
3.
4.
Fasching, Peter A., Thomas E. Delea, Yen‐Shen Lu, et al.. (2021). Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer. Cancer Management and Research. Volume 13. 8179–8189. 4 indexed citations
5.
Kanjanapan, Yada, Sheau Wen Lok, Peter Gibbs, et al.. (2020). Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer. Breast Cancer Research and Treatment. 184(1). 87–95. 3 indexed citations
6.
Boer, Richard de, Rina Hui, Elgene Lim, Belinda Yeo, & Nicholas Zdenkowski. (2020). Optimizing care for younger women with hormone receptor‐positive, HER2‐negative metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology. 16(S5). 3–14. 3 indexed citations
7.
Mansfield, Aaron S., Andrzej Każarnowicz, Nina Karaseva, et al.. (2020). Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Annals of Oncology. 31(2). 310–317. 126 indexed citations
8.
Evans, N., A. Antón, Rachel Wong, et al.. (2020). 51P Real world outcomes in elderly women with HER2-positive advanced breast cancer. Annals of Oncology. 31. S1262–S1262. 2 indexed citations
9.
Lim, Elgene, Jane Beith, Frances Boyle, et al.. (2018). Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2‐non‐amplified metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology. 14(S4). 12–21. 2 indexed citations
10.
Elder, Kenneth, Carolyn Nickson, Dorothy A. Machalek, et al.. (2018). Uptake of adjuvant breast cancer treatments recommended by multi‐disciplinary meetings. ANZ Journal of Surgery. 88(7-8). 745–750. 5 indexed citations
11.
Boer, Richard de, et al.. (2018). Spotlight on the utility of the Oncotype DX<sup>&reg;</sup> breast cancer assay. International Journal of Women s Health. Volume 10. 89–100. 42 indexed citations
12.
Wilcken, Nicholas, Nicholas Zdenkowski, Michelle White, et al.. (2014). Systemic treatment of HER2‐positive metastatic breast cancer: A systematic review. Asia-Pacific Journal of Clinical Oncology. 10(S4). 1–14. 17 indexed citations
13.
Boer, Richard de, Jane Beith, Jacquie Chirgwin, et al.. (2014). Systemic treatment of HER2+ metastatic breast cancer: Clinical conundrums and future perspectives. Asia-Pacific Journal of Clinical Oncology. 10(S4). 15–25. 1 indexed citations
14.
Enserink, Remko, Patricia Bruijning‐Verhagen, Erwin Duizer, et al.. (2014). High Detection Rates of Enteropathogens in Asymptomatic Children Attending Day Care. PLoS ONE. 9(2). e89496–e89496. 73 indexed citations
15.
Day, Jessica, Bernard Yan, Richard de Boer, & Alpha Tsui. (2013). Paraneoplastic cerebellar degeneration associated with squamous cell carcinoma of the lung. Journal of Clinical Neuroscience. 20(10). 1448–1449. 3 indexed citations
16.
Coleman, Robert E., Richard de Boer, Holger Eidtmann, et al.. (2012). Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Annals of Oncology. 24(2). 398–405. 258 indexed citations
17.
Eidtmann, Holger, Richard de Boer, Nigel Bundred, et al.. (2010). Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Annals of Oncology. 21(11). 2188–2194. 229 indexed citations
18.
Lipton, Allan, Guenther G. Steger, Jazmín Meneses Figueroa, et al.. (2008). Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy. Clinical Cancer Research. 14(20). 6690–6696. 118 indexed citations
19.
Lipton, Allan, Guenther G. Steger, Jazmín Meneses Figueroa, et al.. (2007). Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases. Journal of Clinical Oncology. 25(28). 4431–4437. 293 indexed citations
20.
Boer, Richard de. (2000). High-dose chemotherapy in high-risk breast cancer. Breast Cancer Research. 2(1).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claudine Helg Breakdown of academic impact, for papers by Giuseppe Milone Breakdown of academic impact, for papers by Randi Isaacs Breakdown of academic impact, for papers by Yaël C. Cohen Breakdown of academic impact, for papers by João Bosco Oliveira Breakdown of academic impact, for papers by WE Fibbe Breakdown of academic impact, for papers by J. Sieper Breakdown of academic impact, for papers by Pamela G. Kidd Breakdown of academic impact, for papers by J Cahn Breakdown of academic impact, for papers by Chirayu Auewarakul
Rankless by CCL
2026